Plasmodium berghei-infected mice died with low levels of parasitemia after repeated intraperitoneal admin istration (five times at 15 mg kg of body weight" 1 every other day) of the in vitro active antimalarial acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]. Toxicological studies showed that the main cause of death resulted from (S)-HPMPA-induced nephrotoxicity. Although concomitant intraperitoneal administration of the tubular epithelium transport blocker probenecid prevented (S)-HPMPA-induced toxicity, mice eventually died with a high level of parasitemia, despite repeated admin istration of high doses of (S)-HPMPA. The short half-life of (S)-HPMPA in plasma combined with the insusceptibility of the nonreplicative stages of the parasite to (S)-HPMPA could explain this failure to eradicate all parasites. Indeed, a low but sustained (calculated) level of 200 nM (S)-HPMPA in plasma completely cured P. berghei-infected mice. However, these mice, which received a total dose of only 28 mg kg-1 administered via osmotic pumps for 7 days, died because of the toxicity of the drug. These findings indicate that nephrotoxicity hinders the use of (S)-HPMPA as a drug against blood stage parasites. An alternative appli cation of (S)-HPMPA as a potent prophylactic drug is discussed.
Infection with species of the protozoan parasite Plasmodium repeatedly (15). (S)-9-(3-hydroxy-2-phosphonylmethoxyprothreatens approximately one-fourth of the world's population. pyl)cytosine [(S)-HPMPC]-induced nephrotoxicity has been A rapidly developing resistance of the parasite to formerly effective drugs stresses the need for the development of new antimalarial compounds. Previous work showed that the nucleoside phosphonate (£)-9-(3-hydroxy-2-phosadenine [(S')-HPMPA], the prodrug the diphosphorylated active compound, is a potent inhibof mid-schizont stages of both P. falciparum and P. Repeated intraperitoneal administration (four of 20 mg of (S)-HPMPA kg of body weight initial attributed to the active uptake of acyclic nucleotide analogs by organic anion transporters present at both the basolateral and the brush border membranes of the proximal convoluted tu bule cell (6). Cyclic derivation of (S)-HPMPC, resulting in a modification of its charge, elevated the therapeutic index (6). Inhibition of (S)-HPMPC uptake by the organic anion trans port blocker probenecid also reduced nephrotoxicity (6, 12, 14) . Depending on the ratio between tubular secretion and reabsorption of a drug in the presence of probenecid, concom itant administration of probenecid can result in an elevation of the level of the drug in plasma and the half-lives of several drugs in plasma (10), including nucleoside and nucleotide an alogs like zidovudine (17) and (5>HPMPC (8). Therefore, in the case of P. berghei cotreatment with probenecid not only could reduce or prevent (S)-HPMPA-induced nephrotoxicity but also could increase the effectiveness of (5)-HPMPA on after treatment was stopped. Two conditions in asynchronous infections. This report describes the toxicologî 1 / * # ■ (estiin plasma, 0.1 mM, or «=»1,200 times the concentration [IC5()] for in vitro-cultured P. strongly suppressed parasitemia in P. BALB/c mice but did not eliminate all parthis treatment resulted in almost ation of parasites, some of the mice which infected with small numbers of parasites (<0.1 %) surviving mice developed increasing levels of cal effects and antimalarial efficacies of different regimens of t half-life in plasma (5 to 10 min) of acyclic nucle-(,S)-HPMPA in the presence and absence of probenecid.
concert may account for the failure of radical treatment: (i) the oside phosphonates (4, 15, 16) and (ii) a narrow window of susceptibility of erythrocytic parasites to (S)-HPMPA, with schizonts, which constitute a minor part of an asynchronous pari population, inhibited only by (£)-HPMPA
MATERIALS AND METHODS
Death after repeated (S)-HPMPA administration, despite minimal parasitemia, suggests toxicity. The nephrotoxicity of acyclic nucleoside phosphonates has been described in mice and humans (12-14), especially when it is administered Toxicological studies. BALB/c mice were exposed to different doses of intraperitoneally (i.p.) administered (S)-HPMPA on the days indicated in the legend to Fig, 1 . Mice were observed daily for clinical signs, and their body weights were determined on the indicated days. Two mice exposed to four times 80 mg of 1 on clays 0, 4, 7, and 11 . The range of the standard deviation (not shown) was 0.9 to 2.5 g. The body weights of nontreated mice were deter mined up to day 21. Their average body weight (25.9 g) did not increase between day 14 and day 21.
HPMPA kg" 1 ( Fig. 1) as well as two control mice were bled on day 21 after the start of treatment for analysis of enzyme and biochemical parameters (Table 1) 
